Drug | Study | ORR | mPFS | Reference |
Atezolizumab | NCT024093342 (IMPower 110), N = 572 (phase III), atezolizumab vs. chemotherapy (PL-L1 ≥ 50%) | 38.3% vs. 26.8% | 8.1 vs. 5.0 mo. | Herbst et al. 2020 [14] |
Pembrolizumab | NCT02142738 (KeyNote-024), N = 305 (phase III), pembrolizumab vs. chemotherapy (PD-L1 ≥ 50%) | 44.8% vs. 27.8% | 10.3 vs. 6.0 mo. | Reck et al. 2016 [15] |
Nivolumab | NCT02041533 (Checkmate-026), N = 541 (phase III), nivolumab vs. chemotherapy (PD-L1 > 5%) | 26% vs. 31% | 4.2 vs. 5.9 mo. | Carbane et al. 2017 [16] |
Durvalumab | NCT02453282 (MYSTIC), N = 1118 (phase III), durvalumab vs. durvalumab + tremelimumab vs. chemotherapy | 35.6%* vs. 34.4% vs. 37.7% | 4.2* vs. 3.0 vs. 5.4 mo. | Rizvi et al. 2020 [17] |